Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. - Wikidata - awgldk - TriplyDB

Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial.

Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial.

http://www.wikidata.org/entity/Q35128552

about

Biomarkers of acute kidney injury and associations with short- and long-term outcomes The Complex Relationship of Extracorporeal Membrane Oxygenation and Acute Kidney Injury: Causation or Association?NGAL-Siderocalin in kidney disease Clinical adoption of prognostic biomarkers: the case for heart failure Cardiac biomarkers: new tools for heart failure management State of the Art: Newer biomarkers in heart failure Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicability Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations Additive value of blood neutrophil gelatinase-associated lipocalin to clinical judgement in acute kidney injury diagnosis and mortality prediction in patients hospitalized from the emergency department.Effect of glomerular filtration rate impairment on diagnostic performance of neutrophil gelatinase-associated lipocalin and B-type natriuretic peptide as markers of acute cardiac and renal failure in chronic kidney disease patients.Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome.Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review.Evidence of uncoupling between renal dysfunction and injury in cardiorenal syndrome: insights from the BIONICS study.Cardiorenal syndrome type 2: from diagnosis to optimal management.Emerging biomarkers in heart failure and cardiac cachexia Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis.Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: The Rancho Bernardo Study.Urinary Angiotensinogen Level Predicts AKI in Acute Decompensated Heart Failure: A Prospective, Two-Stage Study Lack of significant renal tubular injury despite acute kidney injury in acute decompensated heart failure.Plasma neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury in acute heart failure.Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events.Urinary Biomarkers Improve the Diagnosis of Intrinsic Acute Kidney Injury in Coronary Care Units.Neutrophil gelatinase-associated lipocalin levels are U-shaped in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study-Impact for mortality.Role of Neutrophil Gelatinase-Associated Lipocalin in the Diagnosis and Early Treatment of Acute Kidney Injury in a Case Series of Patients with Acute Decompensated Heart Failure: A Case Series.Incorporating common biomarkers into the clinical management of heart failure Development and Validation of a Risk Score for Prediction of Acute Kidney Injury in Patients With Acute Decompensated Heart Failure: A Prospective Cohort Study in China Heart failure highlights in 2011.The emerging role of biomarkers and bio-impedance in evaluating hydration status in patients with acute heart failure.Experimental biomarkers in heart failure: an update.Thirst in heart failure: a systematic literature review.Neutrophil gelatinase-associated lipocalin as diagnostic and prognostic tool for cardiovascular disease and heart failure.Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin.Heart failure biomarkers.New and emerging biomarkers in left ventricular systolic dysfunction--insight into dilated cardiomyopathy.The use of biomarkers in the patient with heart failure.Clinical use of novel biomarkers in heart failure: towards personalized medicine.Prognostic markers for acute heart failure.Clinical utility of biomarkers in chronic kidney disease and chronic heart failure.Novel biomarkers for heart failure.

P2860

Q26745219-5A3050B3-F07C-4F67-9027-966064B5B82F Q26752386-05E9EDD9-F31D-4DD3-8ACF-7283B27574DF Q26863396-E40C4C07-2337-4177-9EF5-5446AFD5F57C Q26863716-C989E486-6981-422F-BB75-EDC70EFF6839 Q26991726-0EB79311-D656-4160-A022-636C7CE47139 Q27027899-C15DE5F2-13F7-47C6-BB65-91AD265D41B8 Q28081407-E7BC45B5-DF1F-41F8-9819-110DC2F24293 Q28087152-B314D934-FD72-44C0-AC5B-CFD1EC38C041 Q33749925-187EDC57-D10F-47A4-941B-B2C18DDFFBDB Q33754152-78FEFE36-BA65-4090-B832-7425EA07CC14 Q33768050-BC45A7FF-8EAE-46D5-AA93-0F8A77B4F898 Q33970136-662AF893-BDB7-4793-811C-7EC985B7D5BF Q34086935-C3E6FAB8-5859-4B97-AC63-18079C9DAC35 Q34489305-270B8CD5-F294-4900-9C7D-147180C38834 Q34532094-4E2C8602-ED54-411D-833A-ED9B2D3CE76A Q34836097-D3DC8F3C-7E41-4145-8781-62F6F8406216 Q35156585-491D4DC2-6DF9-4F72-822A-0BF868308A15 Q35854126-9DCB0054-9E03-4657-BD65-5CD110D86FE4 Q35903093-C4A59734-0E8D-495F-B978-07CFC811BE05 Q35987008-548F3730-4157-445A-A00A-54D17DAC2C8D Q36093457-E4BA3E17-812F-4771-85B7-1C79D8AC15DA Q36178408-D16010BC-9B5A-48A4-A4CD-082B8366055E Q36195480-AC098FC8-649F-4079-9FB6-595B96225664 Q36282562-E3F1C0E7-D07E-4826-A020-740907FDBFEE Q36679682-552FDB3A-0E05-4E27-9C8F-659FA85C921F Q37347009-2BFDDF4F-E965-4485-A6BB-6CD2552920C9 Q37556084-703FFCB0-C57D-4175-997A-095564D444B2 Q38035177-AC596B18-C167-4EBE-9C42-72978775FFF4 Q38044782-1BD52BA5-F57E-44AD-8E2E-585F9EFE1155 Q38055505-0D970F9C-26CF-422E-989F-86CA95DF2F11 Q38062509-B724A9B8-755A-4FC4-AED7-7C523D9CFEF5 Q38093260-1B370557-C7F9-4F96-8823-D0E398FEE9D8 Q38096829-4B9592DC-A73D-482B-A2C4-31D5CF4EF54A Q38100647-3E3BE0D3-1EF5-4412-BD80-967D307532DF Q38100987-09909773-1158-4116-9409-AF1CB5182F9E Q38104269-3012D4AD-28EC-44D1-B7ED-35516107AC57 Q38109588-017A1709-6499-4F48-A27E-356820819872 Q38116536-27B38035-1E5A-4A84-861B-D9B8D853C01D Q38125509-A5F0E541-9A6C-469A-A016-FE46AF72ED52 Q38131790-6EA56CE5-E934-449A-9612-68F19F1A3C17

P2860

Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial.

http://www.wikidata.org/entity/Q35128552

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Prognostic utility of plasma n ...... heart failure (GALLANT) trial.

@ast

Prognostic utility of plasma n ...... heart failure (GALLANT) trial.

@en

type

label

Prognostic utility of plasma n ...... heart failure (GALLANT) trial.

@ast

Prognostic utility of plasma n ...... heart failure (GALLANT) trial.

@en

prefLabel

Prognostic utility of plasma n ...... heart failure (GALLANT) trial.

@ast

Prognostic utility of plasma n ...... heart failure (GALLANT) trial.

@en

P1433

Q35128552-5DB2E66D-E1CA-4F05-A82D-3D2F4983EECA

P1476

Q35128552-2714CB80-3336-49F6-A9DB-BA8620DA7EEE

P2093

Q35128552-007C164D-0E79-4E87-BC32-EBCA4D21A680

Q35128552-2FA11059-F4CA-4E88-A102-BC9F0AA2C443

Q35128552-3661DEEE-6D5B-4649-98F1-74150AC0C1A1

Q35128552-5896FC66-BFC9-4B00-AA09-1F41C4EFE094

Q35128552-AF32E17F-928A-4D05-9477-C15D3D353809

Q35128552-B7AC2C33-8B6A-4A06-85D0-442989DD961E

Q35128552-E4BB9315-6B0F-4F0B-BEFC-855D384FE8AB

P2860

Q35128552-062D839A-25DB-4925-818F-373684ABDA8A

Q35128552-0C6F7F26-5A50-4570-A9E3-DC1C5A1D31B7

Q35128552-0F176644-FFB5-416A-BFB4-2A7A782270B7

Q35128552-143B68EE-C21A-479C-AC1E-CF550DC3B64E

Q35128552-27347C67-E099-4947-8B5E-AE5A884A0AF4

Q35128552-329B9D26-05DB-430A-AD7A-2721259F79F4

Q35128552-34E9F239-5934-4BD4-8686-800B76BBEF48

Q35128552-355CF400-A546-4EEC-B465-FEC10C76D1F9

Q35128552-35DA78B2-DF14-4222-B81C-A35FF5B84B68

Q35128552-3808F902-6DD9-4883-A831-2BA82EE1605A

P304

Q35128552-A26696E2-A3CD-4951-9916-8287E0ED7E83

P31

Q35128552-8FCEA705-5446-4562-BD94-85CCCE04AE1C

P356

Q35128552-6CF1EF0C-C686-44FD-A752-FD7054C36642

P433

Q35128552-E21BBFE7-DE30-4DE0-A171-369784B9398A

P478

Q35128552-A15D370A-5EEF-46DC-AC32-4D5995EAE8C0

P50

Q35128552-2A01C106-42E7-4185-A866-E23BE2CDFCCA

P577

Q35128552-80547425-51CC-4C2A-9F1E-A8BE60724CA3

P5875

Q35128552-F148F672-3A2A-4DE7-B4AA-73AB2726D0A5

P698

Q35128552-282DA292-3878-421F-BF7B-81F3A5195D8B

P921

Q35128552-423303A1-EBB8-4BB6-85AF-007926AE3476

Q35128552-E6811656-1142-436E-9CED-AC3F7F4844CB

P932

Q35128552-EA80DDE3-67FD-41B1-A635-0CB687E4ACEF

P356

P1433

European Journal of Heart Failure

P1476

Prognostic utility of plasma n ...... heart failure (GALLANT) trial.

@en

P2093

Alan S Maisel

http://www.w3.org/2001/XMLSchema#string

Brian C Hiestand

http://www.w3.org/2001/XMLSchema#string

Christian Mueller

http://www.w3.org/2001/XMLSchema#string

Navaid Iqbal

http://www.w3.org/2001/XMLSchema#string

Paul Clopton

http://www.w3.org/2001/XMLSchema#string

Robert Brikhan

http://www.w3.org/2001/XMLSchema#string

Robert Fitzgerald

http://www.w3.org/2001/XMLSchema#string

P2860

Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure.

Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury.

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

Dual action of neutrophil gelatinase-associated lipocalin.

The cardiorenal syndrome: lessons from the ADHERE database and treatment options.

Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study.

Renal impairment and outcomes in heart failure: systematic review and meta-analysis.

P304

846-851

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURJHF/HFR087

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Dirk J van Veldhuisen

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51523349

http://www.w3.org/2001/XMLSchema#string

P698

21791540

http://www.w3.org/2001/XMLSchema#string

P921

P932

3143832

http://www.w3.org/2001/XMLSchema#string